Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
The safety profile of UBT251 was consistent with incretin-based therapies
There is no conclusive evidence for pancreatic cancer from clinical trials, but it is still considered a potential risk, particularly in patients with type 2 diabetes
This case highlights how hypomagnesemia can be the missing piece in a deteriorating patientand why empiric replacement should be considered when suspicion is high
doi:10.1016/S0140-6736(18)32260-8 53
US$ 24.51
US$ 29.88
US$ 27.47
US$ 21.52
